ImmunoCellular Therapeutics, Ltd. is a clinical stage biotechnology
company developing immune-based therapies for the treatment of brain and other
cancers. The company’s leading product candidate, ICT-107, is a vaccine that
targets antigens associated with glioblastoma multiforme (GBM), the most common
and lethal form of brain cancer. In recent weeks, ImmunoCellular has made
progress toward the initiation of phase III clinical trials for the drug
candidate, announcing an agreement with Caladrius Biosciences, Inc. for
manufacturing services, including processing, packaging, labelling, quality
control testing, release, shipping and storage. Building on this progress,
patient enrollment for the trial is expected to begin by the early fourth
quarter of this year.
When completed, ICT-107 will address a critically underserved market
within the medical industry. According to a report by the American Cancer
Society, an estimated 10,000 new patients are diagnosed with GBM in the United
States each year. Despite advances in surgery, radiation and chemotherapy,
recurrence is a near certainty and the median survival time for newly diagnosed
GBM patients in only 14.6 months. In ImmunoCellular’s phase II trials for
ICT-107, results suggested potential for greatly increased chances of long-term
survival when treated with the company’s novel vaccine.
“We believe that we are on track to initiate the ICT-107 phase III
trial in the late third quarter or fourth quarter of this year, following
completion of the special protocol assessment process with the FDA and
finalization of agreements with cancer cooperative groups and our contract
research organization, which will manage the trial,” Andrew Gengos, chief
executive officer of ImmunoCellular, stated in a news release. “We believe
there is significant value in ImmunoCellular, given the breadth of our
platforms and our preclinical and clinical assets, led by ICT-107.”
The company’s product pipeline also includes a dendritic cell-based
vaccine that targets CD133, an antigen commonly associated with cancer stem
cells. This candidate, known as ICT-121, is nearing the start of phase I
clinical trials, with patient enrollment actively underway.
Moving forward, ImmunoCellular is in position to realize its corporate
goal of becoming an industry-leading commercial-stage cancer immunotherapy
company. Its pipeline of commercially attractive assets could provide the
company with the opportunity to achieve sustainable returns while effectively
transforming the treatment of cancer.
For more information, visit www.imuc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
